MF63

Item no.	HY-13283-50mg
Manufacturer	MedChem Express
CASRN	892549-43-8
Amount	50 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 50 mg 5 mg
Category	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Heart & Blood Cancer
Type	Inhibitors
Specific against	other
Purity	99.55
Citations	[1]Xu D, et al. MF63 [2-(6-chloro-1H-phenanthro[9,10-d]imidazol-2-yl)-isophthalonitrile], a selective microsomal prostaglandin E synthase-1 inhibitor, relieves pyresis and pain in preclinical models of inflammation. J Pharmacol Exp Ther. 2008 Sep;326(3):754-63. \|[2]Tuure L, et al. Regulation of gene expression by MF63, a selective inhibitor of microsomal PGE synthase 1 (mPGES1) in human osteoarthritic chondrocytes. Br J Pharmacol. 2020 Sep;177(18):4134-4146.
Smiles	ClC1=CC(C2=C3C=CC=C2)=C(C4=C3N=C(C5=C(C=CC=C5C#N)C#N)N4)C=C1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	892549-43-8
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	PGE synthase
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	378.81
Product Description	MF63 is a selective and orally active inhibitor of mPGES-1. MF63 reduces the accumulation of PGE2, relieves pyresis, hyperalgesia, and inflammatory pain by inhibiting mPGES-1[1].
Manufacturer - Research Area	Inflammation/Immunology
Solubility	DMSO : 75 mg/mL (ultrasonic; warming; heat to 60°C)
Manufacturer - Pathway	Immunology/Inflammation
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.